In tumor progression and metastasis, invasion and angiogenesis are essential. Among the various factors, matrix metalloproteinases (MMPs) play an important role in tumor invasion, as well as plasminogen activators, which function to degrade the extracellular matrix. Among the 18 MMPs identified to date, MMP-2 and MMP-9 have been reported to be associated with tumor invasion, metastasis and angiogenesis, [1] [2] [3] [4] [5] and these factors have also been identified to have a prognostic impact in various malignancies.
In tumor progression and metastasis, invasion and angiogenesis are essential. Among the various factors, matrix metalloproteinases (MMPs) play an important role in tumor invasion, as well as plasminogen activators, which function to degrade the extracellular matrix. Among the 18 MMPs identified to date, MMP-2 and MMP-9 have been reported to be associated with tumor invasion, metastasis and angiogenesis, [1] [2] [3] [4] [5] and these factors have also been identified to have a prognostic impact in various malignancies. [6] [7] [8] [9] MMP-2 and MMP-9 have specific proteolytic activity against type IV collagen of the basement membrane.
10) The expression of MMP-2, -9 correlates closely with invasive and metastatic potentials of several tumors in vivo. 4, 8, 11) A correlation between angiogenesis and MMPs was also reported. 6) Several MMP inhibitors including Batimastat, [12] [13] [14] [15] [16] [17] [18] [19] [20] Marimastat, 21) AG3340, 22) BPHA, 1) KB-R7785, 23) R94138, 24) CT1746 25) and BAY12-9566 26) have been synthesized as candidate drugs for cancer treatment. Most of them function to diminish the activity of MMP-2, -9, or -7. Antitumor effects of Batimastat on ovarian tumor, 14, 20) melanoma, 19) colon cancer, 18) breast cancer, 16, 17) hemangioma, 9) and lung cancer 12) Here, we examined a potent oral MMP inhibitor, MMI-166, which selectively inhibits MMP-2 and -9. Several MMP inhibitors reduce metastasis in various models by inhibiting angiogenesis. 1, 9, 13, 23) In this study, we examined the anti-tumor and anti-metastatic effects of MMI-166, and examined the microvessel density (MVD) to clarify the antiangiogenesis activity. Synergistic effects of MMP in combination with conventional cytotoxic agents were reported previously, 3, 14, 24, 25) and in this study we also examined the effect of MMI-166 and a conventional cytotoxic agent, mitomycin C (MMC), in a human colon cancer nude mouse model.
MATERIALS AND METHODS

Animals
Male BALB/c nu/nu mice were obtained from Clea, Japan, Inc. (Tokyo). Animals were used for this study at 5 weeks of age. Materials Matrix metalloproteinase inhibitor MMI-166 was kindly provided by Shionogi Co., Ltd. (Osaka). Its in vitro IC 50 values are 2 nM for gelatinase A (MMP-2) and 53 nM for gelatinase B (MMP-9). An aqueous suspension E-mail: otam@hama-med.ac.jp of MMI-166 (a white powder) was prepared by homogenizing the drug in 0.5% carboxymethyl cellulose Na, 0.9% benzyl alcohol and 0.4% Tween 80 in saline. A control solution of the vehicle without MMI-166 was also prepared. MCC was purchased from Kyowa Hakko (Tokyo) and dissolved in saline. Preparation of human colon cancer xenografts Human colon cancer xenograft, TK-4 (a well-differentiated carcinoma line) was used in this study (Fig. 1) . This xenograft was established from surgical specimens in our department and was maintained by serial transplantation in nude mice. In gelatin zymography, TK-4 tumors expressed MMP-2, but the expression of MMP-9 was not recognized (data not shown). Experimental design For the xenograft orthotopic transplantation, tumor tissue specimens weighing 200 mg were sutured onto the surface of the cecum. Mice were randomly divided into 4 groups and the experiment was started on day 5 after transplantation. The groups were the control group treated with the same volume of vehicle, the MMC group in which animals were given MMC i.p. at a dose of 2 mg/kg/week for 5 weeks, the MMI-166 group in which animals were given MMI-166 p.o. at a dose of 200 mg/kg, 6 days/week for 5 weeks, and the combination group in which animals were given MMC i.p. at a dose of 2 mg/kg/week and MMI-166 p.o. at a dose of 200 mg/kg, 6 days/week for 5 weeks. Mice were sacrificed on day 40 after transplantation. The mice were weighed and autopsy was performed immediately. The tumors growing on the cecal wall were removed and weighed. One part of the tumor was placed in 10% formalin, embedded in paraffin, sectioned, and stained with H&E. The other part was placed in Tissue-Tek O.C.T. Compound (Sakura Finetechnical Co., Ltd., Tokyo), and then snap-frozen and stored at −80°C for immunohistochemistry and gelatin zymography. The liver metastases were counted macroscopically and subjected to routine histological examinations (Fig. 2) . Immunohistochemical analysis for MVD Intratumoral microvessels were determined by immunostaining using a rat monoclonal antibody (ER-MP12) with the avidinbiotin-peroxidase complex technique as previously described. 32) For determination of the MVD in transplanted tumors, the three most vascular areas within one section were chosen and the stained vessels were counted under a light microscope at 200-fold magnification. The average count was recorded as the MVD for each animal. Statistical analysis The statistical analysis was performed with Student's t test and the χ 2 test, and P<0.05 was taken as the criterion of statistical significance.
RESULTS
Therapeutic effect on tumor growth and liver metastasis All tumor pieces transplanted in the cecum grew, as previously reported. 33) Actual tumor weights in each group were as follows: control group, 1.102±0.96 g; MMC (Fig. 3) .
Histological difference between the tumors treated with and without MMI-166 was clearly apparent (Fig. 4) . The tumor margin adjacent to normal tissue in the cecal wall could be readily identified in the MMI and the combination groups, whereas cancer nests invaded the cecal submucosa in the control group. Table I shows the numbers of mice with liver metastasis and metastatic foci in the four groups. No liver metastasis developed in the MMI-166 and combination groups (P<0.01), although it was observed in mice of the control groups and in mice of the MMC group. MMC failed to inhibit liver metastasis. Immunohistochemical analysis for MVD In all three treated groups, MVD was significantly reduced compared with the control group. Development of microvessels was inhibited in the three treated groups. MVD in the combination therapy was lowest among the groups, although the difference was not significant (P=0.155 vs. MMC,=0.13 vs. MMI-166) (Fig. 5) . Body weight and spleen weight No significant differences in body weight and spleen weight were found in the 4 groups, and there were no severe side effects in any group (Fig. 6 ).
DISCUSSION
We demonstrated here that the orally active MMP inhibitor, MMI-166, has antimetastatic efficacy. This is the first report to describe the antimetastatic efficacy of an orally active MMP inhibitor in a nude mouse liver-metastatic model. Furthermore, the synergy of antimetastasis and antiangiogenesis actions of this inhibitor and MMC was clearly apparent in our model. Previously, we investigated and reported the antimetastatic effects of various angiogenesis inhibitors, and the inhibitory effect of MMI-166 was as potent as that of TNP-470 or VEGF-neutralizing antibody. 34, 35) Several MMP inhibitors have been demonstrated to have antiangiogenic activity, 1, 9, 13, 23) mainly because the degradation of ECM is essential to the process of angiogenesis. It has been shown in several studies with different 6) and lung cancer. 37) Thymidine phosphorylase expression was also correlated to pro MMP-2 and activated MMP-9 expression. 6) In MMP-2-deficient mice, tumor-induced angiogenesis was suppressed according to dorsal air sac assay, and the implanted tumor volume decreased for B16-BL16 melanoma and Lewis lung carcinoma.
2) MMP-2 is expressed in several tumors 4, 7, 11, 37) and is related to prognosis 19) and angiogenesis. 6) Considering that MMI-166 selectively inhibited both MMP-2 and MMP-9, and only MMP-2 is expressed in TK-4, inhibition of MMP-2 activity of TK-4 is crucial in preventing liver metastasis of this strain (data not shown). MMP-2 has been reported to enhance tumor angiogenesis. Histological findings revealed that MMI-166 was effective in reducing not only tumor angiogenesis, but also tumor invasion. The tumor margin adjacent to normal tissue in the cecal wall could be identified clearly in the groups treated with MMI-166. This suggested that the tumor invasion was inhibited by MMI-166, and this might have contributed to the antimetastatic effect. In the metastatic sites, however, MMP inhibitors may not inhibit the extravasation of tumor cells. Wylie et al. showed by intravital videomicroscopy that Batimastat did not affect the extravasation of cells from the liver circulation, whereas it reduced the mean diameter of liver metastasis after injection of B16F1 melanoma cells in a mouse model. Because MMC also inhibited the MVD in the primary tumors (Fig. 5) , MMC may have a cytotoxic effect on both tumor cells and endothelial cells. However, the number of metastatic foci in the liver was not decreased by MMC treatment. It is possible that MMC may have a cytotoxic effect on endothelial cells after the tumor reaches by a certain volume.
An enhanced effect of MMI-166 and MMC was also demonstrated in the present study. Several reports have revealed synergistic effects of MMP inhibitors and cytotoxic agents in vivo. The combination of either Batimastat or Marimastat and either cisplatin or cyclophosphamide has synergistic antitumor and survival-prolongation effects in lung and ovarian cancer mouse models. 3, 14) The combination of MMC and R94138 showed an increased preventive effect on peritoneal dissemination in a nude mouse model. 24) The mechanisms of antitumor action of these combinations are not yet known. In a study of induction of Fas-mediated apoptosis in Ewing's sarcoma cell lines, a combination effect of MMP inhibitors and doxorubicin was observed. 38) In another report, the combination of Batimastat and interferon γ showed a strong synergistic effect in an ovarian cancer model in vivo. 15) In addition, our previous study revealed an enhanced therapeutic effect of VEGF nuetralizing antibody and MMC.
39) The combi- nation of antiangiogenic therapy and chemotherapy thus appears to be a useful strategy for colorectal cancer. Though the mechanisms of these combination therapies remain unclear, the combination of MMP inhibitors with chemotherapeutic agents or other antiangiogenic agents may be an option for cancer treatment. Pan-MMP inhibitors have been reported to have adverse effects. Marimastat, which inhibits MMP-1, 2, 3, 7, 9, 12, commonly induces musculoskeletal events such as inflammation of the tendons and ligaments. 12, 29) In patients treated with BAY12-9566, which inhibits MMP-2, 3, 9, such musculoskeletal events were not observed in a Phase I study and other early clinical studies. 26, 40, 41) In the present study, MMI-166 did not induce body weight loss or other serious adverse effects, probably because of its narrow inhibitory spectrum.
In conclusion, our results indicate that MMI-166 has potential antimetastatic ability and a synergistic therapeutic effect with MMC. The advantages of MMI-166 in clinical use are as follows. 1) MMI-166 has a small molecular weight and can be orally administered, which may improve patient compliance. 2) The adverse effects are less than those of broad-type MMP inhibitors and cytotoxic agents.
3) The synergistic effect with cytotoxic agents may afford amplified antitumor and antimetastatic potential.
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